Peptide scaffolds — including drug conjugates, cell-penetrating peptides, and pro-apoptotic peptides — show preclinical promise in overcoming multiple forms of drug resistance in colorectal cancer.
5 resistance layers targetedThe proposed MRP Framework classifies peptide strategies by which resistance mechanism they address: efflux pumps, DNA repair, apoptosis evasion, tumor microenvironment, and immune evasion.
What the researchers found
The review identifies several peptide-based strategies showing preclinical promise against drug-resistant colorectal cancer. Peptide-drug conjugates enhance targeted delivery and antitumor effects. Cell-penetrating peptides improve drug uptake into resistant cells. Pro-apoptotic and oncolytic peptides directly induce tumor cell death through mechanisms that bypass standard resistance pathways.
Peptides can also target multiple resistance mechanisms including DNA repair, cell cycle arrest, apoptosis evasion, gene expression changes, and the tumor microenvironment. The authors introduce a Mechanistic Resistance Profiling (MRP) Framework that classifies peptides by the specific resistance layer they target (efflux, repair, apoptosis, tumor microenvironment, and immune evasion) to guide rational combination therapies.
Why it matters
Colorectal cancer is a leading cause of cancer death, and drug resistance severely limits treatment effectiveness. Peptide-based approaches offer a versatile toolkit for attacking resistance through multiple mechanisms simultaneously. If validated clinically, these strategies could restore treatment sensitivity in patients whose cancers have stopped responding to conventional therapies.
How the study worked
This is a narrative review article that synthesizes recent research on peptide-mediated therapies against drug-resistant colorectal cancer. The authors surveyed preclinical studies and clinical evaluations of peptide-drug conjugates, cell-penetrating peptides, pro-apoptotic peptides, oncolytic peptides, immunotherapeutic peptides, and peptide-nanocarrier systems.
What this study cannot tell us
The evidence reviewed is primarily preclinical — most peptide-based strategies discussed have not been validated in human clinical trials. The proposed MRP Framework is a conceptual tool that needs clinical validation. Peptide stability, bioavailability, and manufacturing scalability remain practical challenges. The review does not quantify efficacy across studies with specific outcome data.
How to read the evidence
This is a narrative review of primarily preclinical research. While it provides a useful synthesis of the field, the underlying evidence has not been validated in human clinical trials, placing the overall evidence at an early stage.
When this study was published
Published in 2026, this review captures the latest preclinical developments in peptide-based approaches to cancer drug resistance.
The bigger picture
Peptide therapeutics are increasingly recognized for their versatility in oncology. While antibody-drug conjugates have gained clinical traction, peptide-drug conjugates offer advantages in terms of smaller size, better tissue penetration, and lower immunogenicity. This review positions peptide scaffolds as a complementary approach to existing cancer therapies, particularly for the growing problem of multidrug resistance that affects many colorectal cancer patients.
Questions still open
- Which peptide-based strategies are closest to clinical validation for drug-resistant colorectal cancer?
- Can the Mechanistic Resistance Profiling Framework effectively guide combination therapy selection in practice?
- How do peptide-based approaches compare to antibody-drug conjugates in overcoming cancer drug resistance?
Common questions
Why do colorectal cancers become resistant to treatment?
How can peptides help overcome cancer drug resistance?
Read the original research
Targeting drug resistance in colorectal cancer using peptide-based scaffolds: new frontiers in colorectal cancer therapy.
Nanomedicine (London, England), 21(5), 691-703
Citation
Sen, Sanjukta; Mitra, Sreemoyee; Karati, Dipanjan. (2026). Targeting drug resistance in colorectal cancer using peptide-based scaffolds: new frontiers in colorectal cancer therapy.. Nanomedicine (London, England), 21(5), 691-703. https://doi.org/10.1080/17435889.2026.2628241